American Board of Obstetrics & Gynecology
2006 Annual Report - Gynecologic Oncology
UT Southwestern Medical Center
FELLOW PUBLICATIONS AND PRESENTATIONS
July 1, 2003 to June 30, 2006

                         Richard D. Drake, M.D.  -  2002-2006

PUBLICATIONS:

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW,
    Berkowitz RS, Mok SC.  Osteopontin as an adjunct to CA125 in detecting recurrent
    ovarian cancer.  Clin cancer Res 2004;10:3474-8.

Drake RD, Lin WM, Kiing M, Farrar D, Miller DS, Coleman RL.  Oral dexamethasone
    attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with
    recurrent gynecologic malignancies.  Gynecol Oncol 2004;94:320-4.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.  Phase I clinical trial of weekly
    paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical
    cancer.  Gynecol Oncol 2005;96:168-72.

Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P,
    Miller DS, Karlan BY.  Ovarian preservation in stage I low-grade endometrial
    stromal sarcomas.  Obstet Gynecol 2005;106:1304-8.

Drake RD, Schorge JO.  The activity of taxanes in the treatment of sex cord-stromal
    ovarian tumors.  Article review.  Women's Oncol Rev 2005;5:31-2.

Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO.  Gestational trophoblastic
    disease among Hispanic women: A 21-year hospital-based study.  Gynecol
    Oncol 2006 (In Press).

Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO. 
    Simplifying the pre-evaculation testing strategy for patients with molar
    pregnancy.  J Reprod Med 2006 (In Press).

PRESENTATIONS:

Drake RD, Kim J, Mok SC, Schorge JO.  Osteopontin as an ovarian cancer
    biomarker for monitoring disease status in conjunction with CA125--a
    longitudinal study.  Oral presentation.  Mid-Atlantic Gynecologic Oncology
    Society 18th Annual Meeting, Durham, North Carolina.  October 2003.

Drake RD, Lee H, Rajanbabu R, Kim J, Miller DS, Mok SC, Schorge JO.
    Evaluation of plasma osteopontin in diagnosing and monitoring ovarian
    cancer.  Poster and SGO Travel Grant.  Society of Gynecologic Oncologists
    35th Annual Meeting, San Diego, California.  February 2004.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO.
    Restoration of Slit-2 function: A novel therapeutic option for ovarian
    cancer?  Poster.  Society of Gynecologic Oncologists 35th Annual Meeting,
    San Diego, California.  February 2004.

Drake RD, Kim J, Mok SC, Schorge JO.  Evaluation of plasma osteopontin
    in diagnosing and monitoring ovarian cancer.  Oral presentation.  8th
    Annual National Gynecologic Oncology Fellows' Forum, San Diego, California.
    February 2004.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO.
    Restoration of Slit-2 function: A novel therapeutic option for ovarian cancer?
    Oral presention.  8th Annual National Gynecologic Oncology Fellows'
    Forum, San Diego, California.  February 2004.

Drake RD, Girard L, Lam DL, Minna JD, Schorge JO.  Gene expression profiling
    to predict platinum-sensitivity in ovarian cancer.  Oral presentation and
    National Ovarian Cancer Coalition Scholar-in-Training Award.   American
    Association of Cancer Research 95th Annual Meeting, Orlando, Florida. 
    March 2004.

Lavie I, Rao G, Drake R, Knowles L, Miller D, Schorge JO.  A re-evaluation
    of hCG surveillance in partial hydatidiform moles.  Poster, Joint Meeting
    of the Western Association of Gynecologic Oncologists and The Felix
    Rutledge Society, Monterey, California.  May 2004.

Drake RD, Rao GG, Schorge JO.  Gestational trophoblastic disease among
    Hispanic women: A 20-year experience at Parkland Memorial Hospital.
    Oral presentation.  New England Association of Gynecologic Oncologists
    24th Annual Meeting, Chatham, Massachusetts.  June 2004.

Drake RD, Rao GG, Schorge JO.  Gestational trophoblastic disease among
    Hispanic women: A 20-year experience at Parkland Memorial Hospital.
    Oral presentation.  ACOG District VII Annual Meeting, Washington, D.C.
    October 2004.

Drake RD, Girard L, Lam DL, Minna JD, Schorge JO.  Gene expression
    profiling to predict platinum-sensitivity in ovarian cancer.  Oral
    presentation.  9th Annual National Gynecologic Oncology Fellows'
    Forum, Tuscon, Arizona.  January 2005.

Knowles LM, Drake RD, Ashfaq R, Miller DS, Schorge JO.  Simplifying
    the diagnostic workup of molar pregnancy.  Poster.  American
    College of Obstetricians and Gynecologists 53rd Annual Meeting,
    San Francisco, California.  May 2005.

Drake RD, Rao GG, Schorge JO.  The incidence of GTD in Hispanic
    women: A 20year experience at Parkland Memorial Hospital. 
    Poster.  American College of Obstetricians and Gynecologists
    53rd Annual Meeting, San Francisco, California.  May 2005.

                   Lynne M. Knowles, M.D. - 2003-2007

PUBLICATIONS:

Schorge JO, Knowles LM, Lea JS.  Adenocarcinoma of the cervix.
    Curr Treat Options Oncol 2004;5:119-27.

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO.
    Retrospective cohort study of surgical staging for ovarian low
    malignant tumors.  Am J Obstet Gynecol 2006;194:e20-22.


PRESENTATIONS:

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO.
    Restoration of Slit-2 function: A novel therapeutic option for ovarian
    cancer?  Poster.  Society of Gynecologic Oncologists 35th Annual
    Meeting, San Diego, California.  February 2004.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO.
    Resporation of Slit-2 function: A novel therapeutic option for ovarian
    cancer?  Oral presentation.  8th Annual National Gynecologic
    Oncology Fellows' Forum, San Diego, California.  February 2004.

Lavie I, Rao G, Drake R, Knowles L, Miller D, Schorge JO.  A re-
    evaluation of hCG surveillance in partial hydatidiform moles.  Poster.
    Joint Meeting of the Western Association of Gynecology Oncologists
    and The Felix Rutledge Society, Monterey, California.  May 2004. 

Knowles LM, Nandi A, Gurnani P, Miller DS, Mok SC, Rosenblatt K,
    Schorge JO.  Serum proteomic profiling to predict early relapse in
    ovarian cancer.  Main Plenary Oral Presentation, Society of
    Gynecologic Oncologists' 36th Annual Meeting, Miami, Florida.
    March 2005.

Knowles LM, Drake RD, Ashfaq R, Miller DS, Schorge JO.  Simplifying
    the diagnostic workup of molar pregnancy.  Poster.  American
    College of Obstetricians and Gynecologists 53rd Annual Meeting,
    San Francisco, California.  May 2005.

Gao J, Knowles LM, Nandi A, Gurnani P, Rosenblatt K, Schorge JO.
    Diagnosis of early relapse of ovarian cancer using an novel feature
    selection method.  Oreal presentation, IEEE 5th Symposium on
    Bioinformatics and Bioengineering, Minneapolis, Minnesota.
    October 2005.

Oh J, Gao J, Nandi A, Gurnani P, Knowles L, Schorge J, Rosenblatt K.
    Multicategory classification using extended SVM-RFE and Markov
    blanket on SELDI-TOF mass spectrometry data.  Proc IEEE
    Symposium on Computational Intelligence in Bioinformatics and
    Computational Biology (CIBCB), San Diego, California.
    November 2005.

Oh J, Gao J, Nandi A Gurnani P, Knowles L, Schorge J. Rosenblatt K.
    Diagnosis of early relapse in ovarian cancer using serum proteomics.
    16th International Conference on Genome Informatics, Yokohama,
    Japan.  December 2005.

                    Shawna L. Bull, M.D. - 2004-2008

PUBLICATIONS:

Schorge JO, Bull SL, Lea JS.  Current management of in situ and
    invasive cervical adenocarcinoma.  Curr Women's Health Rev
    2005;1:185-96.

Bull SL, Schorge JO.  A study of the impact of adding HPV types
    to cervical cancer screening and triage tests.  Article review.  
    Women's Oncol Rev 2005;5:99-100.

PRESENTATIONS:

Bull SL, Schorge JO, Peyton MJ, Miller DS, Lea JS.  Lack of mutations
    within the EGFR tyrosine kinase domain suggests resistance to
    gefitinib in ovarian cancer cells.  Oral presentation.  9th Annual
    National Gynecologic Oncology Fellows' Forum, Tuscon, Arizona.
    January 2005.

Bull SL, Schorge JO, Peyton MJ, Miller DS, Lea JS.  Lack of mutations
    within the EGFR tyrosine kinase domain suggests resistance to
    gefitinib in ovarian cancer cells.  Poster.  Society of Gynecologic
    Oncologists' 36th Annual Meeting, Miami, Florida.  March 2005.

Lea JS, Kalahasti G, Peyron MJ, Bull SL, Miller DS, Minna JD.
    Targeted inhibition of EGFR alone in cervical cancers may not
    produce a clinical response.  Poster.  Society of Gynecologic
    Oncologists' 37th Annual Meeting, Palm Springs, California.
    March 2006.

Bull SL, Garner EI, Walsh C, Gehrig PA, Schorge JO.  Fertility-
    sparing surgery for 102 patients with cervical adenocarcinoma
    in situ.  Society of Gynecologic Oncologists 37th Annual Meeting,
    Palm Springs, California.  March 2006.

Bull SL, Garner EI Walsh C, Gehrig PA, Schorge JO.  Is it worth the
    risk to preserve fertility in cervical adenocarcinoma in situ?
    Western Association of Gynecologi Oncologists 35th Annual
    Meeting, Lake Tahoe, California.  May 2006.

Bull SL, Castro-Rivera E, Miller DS, Brekken RA , Lea JS. 
    Modulation of SPARC as a novel therapeutic option for
    platinum-resistant ovarian cancer cell lines.  Western
    Association of Gynecology Oncologists 35th Annual Meeting,
    Lake Tahoe, California.  May 2006.

                 Thomas P. Heffernan, M.D. - 2005-2009

PUBLICATIONS:

None

PRESENTATIONS:

Heffernan TP, Minna JD, Miller DS, Schorge JO, Lea JS.  Loss of
    secreted protein rich and acidic in systeine (SPARC) may predict
    cervical carcinogenesis and modulate resistance to cytotoxic
    chemotherapy.  Society of Gynecologic Oncologists 37th Annual
    Meeting, Palm Springs, California.  March 2006.

                  Shana N. Wingo, M.D. - 2006-2010

PUBLICATIONS:

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO.
    Retrospective cohort study of surgical staging for ovarian
    low malignant tumors.  Am J Obstet Gynecol 2006;194:e20-22

PRESENTATIONS:

None